PrEPVacc leaders contribute to future design of HIV prevention trials
PrEPVacc experts have been contributing their insights to the Global HIV Vaccine Enterprise virtual workshop series on design approaches for future HIV prevention efficacy trials.
Dr Eugene Ruzagira, PrEPVacc Trial Director based at the MRC/UVRI and LSHTM Research Unit, spoke during the first session that examined current efficacy trial design approaches and presented "PREPVACC Concepts – Registrational Cohort and Prequalification Period (S1-07)"
Professor Sheena McCormack, PrEPVacc’s Project Lead who is based at MRC Clinical Trials Unit at UCL, spoke during the 6 November live panel session that explored the topic of future design approaches for settings where all participants are on active prevention, specifically anti retroviral (ARV) based prevention.